What We're Reading: Page 208
Industry reads hand-picked by our editors
Sep 19, 2019
Sep 18, 2019
-
STAT
'Reasonable' pricing could limit the cost for Zolgensma in France
-
Science
A new sickle cell drug could soon get U.S. approval. But does it work?
-
Reuters
U.S. Senators urge FTC to scrutinize multi-billion dollar pharma mergers
-
S&P
'Right to Try' twin startups, Trump's claims stir confusion, bioethicists say
Sep 17, 2019
-
The Wall Street Journal
Purdue Pharma Looks to Extend Bankruptcy Shield to Sacklers
-
Reuters
With a backup to the backup, insulin makers say they're primed for Brexit
-
San Francisco Business Times
A look inside Merck's new Peninsula research 'superhub'
-
The Columbus Dispatch
Former Dublin couple accused of stealing Nationwide Children's trade secrets
Sep 16, 2019
-
The Wall Street Journal
The Startup That Manipulated Data to Get a Miracle Drug to Market
-
Reuters
U.S. court let Merck hide secrets about popular drug's risks
-
Bloomberg
Plaintiffs in Ohio Opioid Trial Ask for $8 Billion in Damages
-
The Sunday Times
Neil Woodford’s Benevolent AI sees valuation slashed
Sep 13, 2019
Sep 12, 2019
-
Bloomberg
How Carcinogen-Tainted Generic Drug Valsartan Got Past the FDA
-
Associated Press
Some states say they'll keep fighting Purdue Pharma in court
-
STAT
In a CRISPR first, therapy aiming to cure HIV patient appears safe
-
The New York Times
Why Aren’t There Better Cancer Drugs? Scientists May Have Picked the Wrong Targets
Previous
